HomeCompareSOLLF vs MRK

SOLLF vs MRK: Dividend Comparison 2026

SOLLF yields 5.41% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $10.1K in total portfolio value
10 years
SOLLF
SOLLF
● Live price
5.41%
Share price
$0.09
Annual div
$0.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.6K
Annual income
$0.55
Full SOLLF calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — SOLLF vs MRK

📍 MRK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSOLLFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SOLLF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SOLLF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SOLLF
Annual income on $10K today (after 15% tax)
$460.00/yr
After 10yr DRIP, annual income (after tax)
$0.47/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, MRK beats the other by $807.28/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SOLLF + MRK for your $10,000?

SOLLF: 50%MRK: 50%
100% MRK50/50100% SOLLF
Portfolio after 10yr
$25.7K
Annual income
$475.43/yr
Blended yield
1.85%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

SOLLF
No analyst data
Altman Z
0.4
Piotroski
3/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SOLLF buys
0
MRK buys
0
No recent congressional trades found for SOLLF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSOLLFMRK
Forward yield5.41%3.25%
Annual dividend / share$0.00$3.08
Payout ratio50%42%
1-year div growth0%5.5%
5-year div CAGR-50%8.2%
Portfolio after 10y$20.6K$30.7K
Annual income after 10y$0.55$950.29
Total dividends collected$550.00$6.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SOLLF vs MRK ($10,000, DRIP)

YearSOLLF PortfolioSOLLF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$10,971$270.59$11,192$351.54$221.00MRK
2$11,877$138.72$12,524$392.70$647.00MRK
3$12,779$70.18$14,015$438.65$1.2KMRK
4$13,709$35.28$15,682$489.96$2.0KMRK
5$14,686$17.69$17,547$547.23$2.9KMRK
6$15,723$8.85$19,632$611.16$3.9KMRK
7$16,828$4.43$21,963$682.53$5.1KMRK
8$18,008$2.22$24,571$762.18$6.6KMRK
9$19,270$1.11$27,486$851.08$8.2KMRK
10$20,619$0.55$30,745$950.29$10.1KMRK

SOLLF vs MRK: Complete Analysis 2026

SOLLFStock

Shui On Land Limited, an investment holding company, develops and sells properties in the Chinese Mainland. It operates through four segments: Property Development, Property investment, Property Management, and Construction. The company develops and sells residential and commercial properties; and leases offices and commercial/mall properties. It also provides property management services; construction, interior fitting-out, renovation, and maintenance services for building premises; and debt financing and management services. The company was incorporated in 2004 and is headquartered in Shanghai, the People's Republic of China.

Full SOLLF Calculator →

MRKHealthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this SOLLF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SOLLF vs SCHDSOLLF vs JEPISOLLF vs OSOLLF vs KOSOLLF vs MAINSOLLF vs JNJSOLLF vs ABBVSOLLF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.